The Experts below are selected from a list of 6579 Experts worldwide ranked by ideXlab platform
Y. J. Chang - One of the best experts on this subject based on the ideXlab platform.
-
Semen Cryopreservation of yellow croaker Larimichthys polyactis
Reviews in Fish Biology and Fisheries, 2011Co-Authors: Hyun-jeong Lim, Byung-hwa Min, M. W. Park, Y. J. ChangAbstract:The effects of various extenders and cryoprotectants on movable spermatozoa ratio (MSR), spermatozoa velocity (SV) and duration of spermatozoa motility (DSM) of post-thawed spermatozoa were examined. The MSR, SV and DSM of post-thawed sperm in artificial seminal plasma (ASP) extender were higher than those in marine fish Ringer’s solution (MFRS) extender (P < 0.01) and was not significantly different from that of fresh sperm. No significant differences were observed in the motility parameters between fresh spermatozoa and frozen-thawed spermatozoa cryopreserved with ASP extender supplement 10% EG (ethylene glycol) cryoprotectant. Using the above method, yellow croaker Semen was cryopreserved with extender ASP and 10% EG. As a result, at the spermatozoa/egg ratio of 100,000:1, the fertilization rate and hatching rate of the frozen-thawed spermatozoa cryopreserved for 1 week or 1 year in liquid nitrogen (45.7 ± 3.2% and 27.2 ± 5.0% or 37.5 ± 4.4% and 27.2 ± 5.0%) were similar to that of fresh spermatozoa (51.0 ± 3.1% and 36.7 ± 2.2%). There was a small alternation of shape in cryopreserved spermatozoa compared with fresh spermatozoa. In conclusion, the optimal conditions for yellow croaker Semen Cryopreservation are ASP extender supplement 10% EG cryoprotectant. This is the first report on Semen Cryopreservation of yellow croaker Larimichthys polyactis.
-
Semen Cryopreservation of yellow croaker Larimichthys
2011Co-Authors: Y. J. ChangAbstract:The effects of various extenders and cry- oprotectants on movable spermatozoa ratio (MSR), spermatozoa velocity (SV) and duration of spermato- zoa motility (DSM) of post-thawed spermatozoa were examined. The MSR, SV and DSM of post-thawed sperm in artificial seminal plasma (ASP) extender were higher than those in marine fish Ringer's solution (MFRS) extender (P \ 0.01) and was not significantly different from that of fresh sperm. No significant differences were observed in the motility parameters between fresh spermatozoa and frozen-thawed sper- matozoa cryopreserved with ASP extender supplement 10% EG (ethylene glycol) cryoprotectant. Using the above method, yellow croaker Semen was cryopre- served with extender ASP and 10% EG. As a result, at the spermatozoa/egg ratio of 100,000:1, the fertiliza- tion rate and hatching rate of the frozen-thawed spermatozoa cryopreserved for 1 week or 1 year in liquid nitrogen (45.7 ± 3.2% and 27.2 ± 5.0% or 37.5 ± 4.4% and 27.2 ± 5.0%) were similar to that of fresh spermatozoa (51.0 ± 3.1% and 36.7 ± 2.2%). There was a small alternation of shape in cryopre- served spermatozoa compared with fresh spermatozoa. In conclusion, the optimal conditions for yellow croaker Semen Cryopreservation are ASP extender supplement 10% EG cryoprotectant. This is the first report on Semen Cryopreservation of yellow croaker Larimichthys polyactis.
Christian Fuglesang S Jensen - One of the best experts on this subject based on the ideXlab platform.
-
optimizing human Semen Cryopreservation by reducing test vial volume and repetitive test vial sampling
Fertility and Sterility, 2015Co-Authors: Christian Fuglesang S Jensen, Walter R Parker, A M Rocha, Laura M Keller, Timothy G Schuster, Jens Sonksen, Gary D. SmithAbstract:Objective To investigate optimal test vial (TV) volume, utility and reliability of TVs, intermediate temperature exposure (−88°C to −93°C) before cryostorage, cryostorage in nitrogen vapor (VN 2 ) and liquid nitrogen (LN 2 ), and long-term stability of VN 2 cryostorage of human Semen. Design Prospective clinical laboratory study. Setting University assisted reproductive technology (ART) laboratory. Patient(s) A total of 594 patients undergoing Semen analysis and Cryopreservation. Intervention(s) Semen analysis, Cryopreservation with different intermediate steps and in different volumes (50–1,000 μL), and long-term storage in LN 2 or VN 2 . Main Outcome Measure(s) Optimal TV volume, prediction of cryosurvival (CS) in ART procedure vials (ARTVs) with pre-freeze Semen parameters and TV CS, post-thaw motility after two- or three-step Semen Cryopreservation and cryostorage in VN 2 and LN 2 . Result(s) Test vial volume of 50 μL yielded lower CS than other volumes tested. Cryosurvival of 100 μL was similar to that of larger volumes tested. An intermediate temperature exposure (−88°C to −93°C for 20 minutes) during Cryopreservation did not affect post-thaw motility. Cryosurvival of TVs and ARTVs from the same ejaculate were similar. Cryosurvival of the first TV in a series of cryopreserved ejaculates was similar to and correlated with that of TVs from different ejaculates within the same patient. Cryosurvival of the first TV was correlated with subsequent ARTVs. Long-term cryostorage in VN 2 did not affect CS. Conclusion(s) This study provides experimental evidence for use of a single 100 μL TV per patient to predict CS when freezing multiple ejaculates over a short period of time ( 2 provides a stable and safe environment over time.
Gary D. Smith - One of the best experts on this subject based on the ideXlab platform.
-
optimizing human Semen Cryopreservation by reducing test vial volume and repetitive test vial sampling
Fertility and Sterility, 2015Co-Authors: Christian Fuglesang S Jensen, Walter R Parker, A M Rocha, Laura M Keller, Timothy G Schuster, Jens Sonksen, Gary D. SmithAbstract:Objective To investigate optimal test vial (TV) volume, utility and reliability of TVs, intermediate temperature exposure (−88°C to −93°C) before cryostorage, cryostorage in nitrogen vapor (VN 2 ) and liquid nitrogen (LN 2 ), and long-term stability of VN 2 cryostorage of human Semen. Design Prospective clinical laboratory study. Setting University assisted reproductive technology (ART) laboratory. Patient(s) A total of 594 patients undergoing Semen analysis and Cryopreservation. Intervention(s) Semen analysis, Cryopreservation with different intermediate steps and in different volumes (50–1,000 μL), and long-term storage in LN 2 or VN 2 . Main Outcome Measure(s) Optimal TV volume, prediction of cryosurvival (CS) in ART procedure vials (ARTVs) with pre-freeze Semen parameters and TV CS, post-thaw motility after two- or three-step Semen Cryopreservation and cryostorage in VN 2 and LN 2 . Result(s) Test vial volume of 50 μL yielded lower CS than other volumes tested. Cryosurvival of 100 μL was similar to that of larger volumes tested. An intermediate temperature exposure (−88°C to −93°C for 20 minutes) during Cryopreservation did not affect post-thaw motility. Cryosurvival of TVs and ARTVs from the same ejaculate were similar. Cryosurvival of the first TV in a series of cryopreserved ejaculates was similar to and correlated with that of TVs from different ejaculates within the same patient. Cryosurvival of the first TV was correlated with subsequent ARTVs. Long-term cryostorage in VN 2 did not affect CS. Conclusion(s) This study provides experimental evidence for use of a single 100 μL TV per patient to predict CS when freezing multiple ejaculates over a short period of time ( 2 provides a stable and safe environment over time.
-
Fertility considerations, counseling, and Semen Cryopreservation for males prior to the initiation of cancer therapy.
Clinical journal of oncology nursing, 2004Co-Authors: Marcia Leonard, Karen Hammelef, Gary D. SmithAbstract:An innovative program jointly sponsored by members of the departments of obstetrics and urology and the Comprehensive Cancer Center at the University of Michigan began in 2002. The Fertility Counseling and Gamete Cryopreservation Program (FCGCP) was created to provide counseling and education about therapy-induced infertility to newly diagnosed patients with cancer as well as facilitating the Semen Cryopreservation process. Unlike most sperm banking facilities in this country, this program is coordinated by an oncology nurse practitioner whose understanding of cancer and cancer treatments provides patients and staff with a unique perspective. Oncology staff misconceptions about sperm banking were addressed through intensive staff education programs. Patient education materials covering all aspects of infertility and sperm banking were developed and made available in patient care areas and on the Internet. Material aimed at young adolescents and their parents is prominent. Developmentally appropriate discussions are held with adolescent patients and their parents, both individually and together. Communication among patients and their families, the oncology team, and the sperm bank is maintained, permitting efficient and timely service. FCGCP provides an important service by affording all males with cancer the potential to father a child in the future.
Marry M. Van Den Heuvel-eibrink - One of the best experts on this subject based on the ideXlab platform.
-
Electroejaculation as a method of fertility preservation in boys diagnosed with cancer: a single-center experience and review of the literature
Fertility and sterility, 2014Co-Authors: Maria C. Adank, Niels J. Van Casteren, Wendy Van Dorp, Marij Smit, Joop S.e. Laven, Rob Pieters, Marry M. Van Den Heuvel-eibrinkAbstract:Objective To evaluate the feasibility of electroejaculation to perform Semen Cryopreservation in pubertal boys before gonadotoxic therapy and to review the literature on this topic. Design Retrospective cohort study and review of the literature. Setting Academic children's hospital. Patient(s) Boys diagnosed with cancer to whom sperm Cryopreservation was offered before the start of gonadotoxic therapy. Intervention(s) We studied the outcome of electroejaculation, including patient characteristics, hormone levels, and pretreatment Semen parameters. Main Outcome Measure(s) Semen Cryopreservation. Result(s) Pretreatment Semen samples were obtained by masturbation in 106/114 boys with cancer, of which 78/106 were adequate for preservation. Electroejaculation was offered to 11 boys, of which three of 11 samples appeared adequate for preservation. Reviewing all reported electroejaculation cases in children with cancer in the literature, 13/29 (45%) cases were successful. Testosterone levels were higher in patients with successful sperm yield obtained by electroejaculation (median, 8.3 nmol/L [5.2–42.4] in successful harvests, vs. median 1.7 nmol/L [0.01–17.9] in unsuccessful harvests). Conclusion(s) Semen Cryopreservation should be offered to all pubertal boys diagnosed with cancer. If masturbation fails, electroejaculation can be considered as a useful option for Semen Cryopreservation and leads to adequate material for Cryopreservation in about half of the cases.
-
Semen Cryopreservation in pubertal boys before gonadotoxic treatment and the role of endocrinologic evaluation in predicting sperm yield.
Fertility and sterility, 2007Co-Authors: Niels J. Van Casteren, Gert R. Dohle, Johanens C. Romijn, Sabine M.p.f. De Muinck Keizer-schrama, R. F. A. Weber, Marry M. Van Den Heuvel-eibrinkAbstract:Objective To evaluate the feasibility of Semen Cryopreservation in pubertal boys before they receive gonadotoxic therapy and to identify which pretreatment parameters might predict successful Cryopreservation. Design Retrospective data analysis. Setting Tertiary fertility center, academic children's hospital. Patient(s) Between 1995 and 2005, 80 boys (median age 16.6 years, range 13.7–18.9 years) consulted the outpatient clinic of andrology for Semen Cryopreservation before a potentially gonadotoxic treatment. Intervention(s) We assessed the pretreatment Semen parameters, hormone levels, and patients' characteristics. Main Outcome Measure(s) Measurement of the number of adolescents able to cryopreserve Semen. Result(s) Thirteen boys were unable to produce Semen by masturbation. In 53 boys Semen quality was adequate for Cryopreservation. In 14 patients Semen analysis did not show motile spermatozoa, and therefore Semen Cryopreservation could not be performed. Although inhibin B showed a strong correlation with sperm count, no significant difference was found in serum T, inhibin B, LH, and FSH levels in the patients with or without successful sperm yield. Moreover, median age was not different between patients with and without a successful sperm yield. Conclusion(s) Semen Cryopreservation in boys is a feasible method to preserve spermatozoa before gonadotoxic therapy is started and should be offered to all pubertal boys despite their young age. Serum hormone levels do not predict sperm yield.
Sophie D. Fosså - One of the best experts on this subject based on the ideXlab platform.
-
twenty years experience with Semen Cryopreservation in testicular cancer patients who needs it
European Urology, 2005Co-Authors: Henriette Magelssen, Trine B. Haugen, V. Von Düring, Kari Klungsøyr Melve, B. Sandstad, Sophie D. FossåAbstract:Abstract Purpose: To evaluate the role of Semen Cryopreservation (SCP) in the fertility saving management of testicular cancer (TC) patients, treated at the Norwegian Radium Hospital between 1983 and 2002. Patients and methods: 422 of 1388 newly diagnosed TC patients had SCP All patients were followed up for post-treatment paternity. Results: During the 20 years study period, by 2002 an increasing percentage of patients had pre-treatment SCP, reaching 43% after 1994. Twenty-nine (7%) of the 422 patients with SCP had used their frozen Semen for assisted reproductive techniques (ART) at least once to achieve fatherhood. Pregnancies were achieved in 16 of these patients' partners, but two of these pregnancies ended in abortions. 67(17%) of 393 men with SCP fathered at least one child without use of frozen Semen. The comparable figures for those without SCP were 205 out of 966(21%). Twenty years after orchiectomy the cumulative incidence of first post-treatment fatherhood was 47% for the 393 patients who had SCP but did not use it for ART, and 34% for the 966 patients without SCP ( p =0.12). Conclusion: If offered, about 50% of the young and middle-aged patients newly diagnosed with TC are interested in pre-treatment SCP. Though our study reveals that a considerable number of TC patients referred to SCP, achieve fatherhood without the use of frozen Semen, the psychological impact of pre-treatment Cryopreservation is undeniable. Furthermore, for some TC survivors ART with cryopreserved sperm offers the only chance of post-treatment paternity.
-
Twenty years experience with Semen Cryopreservation in testicular cancer patients: who needs it?
European urology, 2005Co-Authors: Henriette Magelssen, Trine B. Haugen, V. Von Düring, Kari Klungsøyr Melve, B. Sandstad, Sophie D. FossåAbstract:Abstract Purpose: To evaluate the role of Semen Cryopreservation (SCP) in the fertility saving management of testicular cancer (TC) patients, treated at the Norwegian Radium Hospital between 1983 and 2002. Patients and methods: 422 of 1388 newly diagnosed TC patients had SCP All patients were followed up for post-treatment paternity. Results: During the 20 years study period, by 2002 an increasing percentage of patients had pre-treatment SCP, reaching 43% after 1994. Twenty-nine (7%) of the 422 patients with SCP had used their frozen Semen for assisted reproductive techniques (ART) at least once to achieve fatherhood. Pregnancies were achieved in 16 of these patients' partners, but two of these pregnancies ended in abortions. 67(17%) of 393 men with SCP fathered at least one child without use of frozen Semen. The comparable figures for those without SCP were 205 out of 966(21%). Twenty years after orchiectomy the cumulative incidence of first post-treatment fatherhood was 47% for the 393 patients who had SCP but did not use it for ART, and 34% for the 966 patients without SCP ( p =0.12). Conclusion: If offered, about 50% of the young and middle-aged patients newly diagnosed with TC are interested in pre-treatment SCP. Though our study reveals that a considerable number of TC patients referred to SCP, achieve fatherhood without the use of frozen Semen, the psychological impact of pre-treatment Cryopreservation is undeniable. Furthermore, for some TC survivors ART with cryopreserved sperm offers the only chance of post-treatment paternity.
